Doxazosin

A cell-permeable naphthoic acid compound that exhibits selective affinity and agonistic potency toward RAR&#946 and RAR&#947 over RAR&#945 (Kd = 34, 130, and 1100 nM, respectively AC 50 = 2.3, 9.

Anti-DNAH11 dynein, axonemal, heavy chain 11, 25ul UN 1687 6

Anti-ITIH3 inter-alpha-trypsin inhibitor heavy chain 3, 100u

General description PTEN induced putative kinase 1 (PINK1) is a serine/threonine mitochondrial kinase. The 581 amino acid protein has an amino terminal mitochondrial target sequence, a putative transmembrane domain, a kinase domain and an

BLOCK 96 WELLPLATE

Block Module 96 Well

Immunogen 19 amino acids near the center of human COMMD7. Application Used as a blocking peptide in immunoblotting applications.

Dabuzalgron (Ro 115-1240) is a selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function.

Dabuzalgron (Ro 115-1240) is a selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function.

Dabuzalgron (Ro 115-1240) is a selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function.

Dabuzalgron (Ro 115-1240) is a selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function.

A class III antiarrhythmic agent that prolongs cardiac action potential duration by selectively inhibiting the rapidly activating inward rectifying component of net delayed rectifier K+ current (IC₅₀ = 31.5 nM in guinea pig